Logo image of VERA

VERA THERAPEUTICS INC (VERA) Stock Fundamental Analysis

USA - NASDAQ:VERA - US92337R1014 - Common Stock

29.995 USD
-0.41 (-1.36%)
Last: 10/28/2025, 2:58:06 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VERA. VERA was compared to 534 industry peers in the Biotechnology industry. While VERA seems to be doing ok healthwise, there are quite some concerns on its profitability. VERA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VERA has reported negative net income.
VERA had a negative operating cash flow in the past year.
VERA had negative earnings in each of the past 5 years.
VERA had a negative operating cash flow in each of the past 5 years.
VERA Yearly Net Income VS EBIT VS OCF VS FCFVERA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of VERA (-37.73%) is better than 61.61% of its industry peers.
With a decent Return On Equity value of -46.61%, VERA is doing good in the industry, outperforming 67.98% of the companies in the same industry.
Industry RankSector Rank
ROA -37.73%
ROE -46.61%
ROIC N/A
ROA(3y)-48.55%
ROA(5y)-56.49%
ROE(3y)-78.86%
ROE(5y)-77.96%
ROIC(3y)N/A
ROIC(5y)N/A
VERA Yearly ROA, ROE, ROICVERA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VERA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VERA Yearly Profit, Operating, Gross MarginsVERA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

VERA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VERA has been increased compared to 5 years ago.
Compared to 1 year ago, VERA has an improved debt to assets ratio.
VERA Yearly Shares OutstandingVERA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
VERA Yearly Total Debt VS Total AssetsVERA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

VERA has an Altman-Z score of 8.90. This indicates that VERA is financially healthy and has little risk of bankruptcy at the moment.
VERA has a Altman-Z score of 8.90. This is amongst the best in the industry. VERA outperforms 80.71% of its industry peers.
A Debt/Equity ratio of 0.16 indicates that VERA is not too dependend on debt financing.
VERA has a worse Debt to Equity ratio (0.16) than 66.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 8.9
ROIC/WACCN/A
WACCN/A
VERA Yearly LT Debt VS Equity VS FCFVERA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 17.03 indicates that VERA has no problem at all paying its short term obligations.
VERA has a better Current ratio (17.03) than 92.88% of its industry peers.
A Quick Ratio of 17.03 indicates that VERA has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 17.03, VERA belongs to the best of the industry, outperforming 92.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.03
Quick Ratio 17.03
VERA Yearly Current Assets VS Current LiabilitesVERA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for VERA have decreased strongly by -60.54% in the last year.
EPS 1Y (TTM)-60.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-93.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VERA will show a very strong growth in Earnings Per Share. The EPS will grow by 24.85% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-51.61%
EPS Next 2Y-31.31%
EPS Next 3Y-7.66%
EPS Next 5Y24.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VERA Yearly Revenue VS EstimatesVERA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B
VERA Yearly EPS VS EstimatesVERA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VERA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERA Price Earnings VS Forward Price EarningsVERA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERA Per share dataVERA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

VERA's earnings are expected to decrease with -7.66% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.31%
EPS Next 3Y-7.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VERA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERA THERAPEUTICS INC

NASDAQ:VERA (10/28/2025, 2:58:06 PM)

29.995

-0.41 (-1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners109.87%
Inst Owner Change0.84%
Ins Owners1.05%
Ins Owner Change0%
Market Cap1.91B
Revenue(TTM)N/A
Net Income(TTM)-218282000
Analysts82.11
Price Target66.02 (120.1%)
Short Float %15.45%
Short Ratio6.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.61%
Min EPS beat(2)-43.18%
Max EPS beat(2)-8.04%
EPS beat(4)1
Avg EPS beat(4)-15.56%
Min EPS beat(4)-43.18%
Max EPS beat(4)15.67%
EPS beat(8)2
Avg EPS beat(8)-9.12%
EPS beat(12)3
Avg EPS beat(12)-9.96%
EPS beat(16)5
Avg EPS beat(16)-7.77%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.25%
PT rev (3m)0.17%
EPS NQ rev (1m)3.09%
EPS NQ rev (3m)-34.95%
EPS NY rev (1m)5.5%
EPS NY rev (3m)-24.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.09
P/tB 4.09
EV/EBITDA N/A
EPS(TTM)-3.58
EYN/A
EPS(NY)-4.74
Fwd EYN/A
FCF(TTM)-2.92
FCFYN/A
OCF(TTM)-2.9
OCFYN/A
SpS0
BVpS7.34
TBVpS7.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -37.73%
ROE -46.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.55%
ROA(5y)-56.49%
ROE(3y)-78.86%
ROE(5y)-77.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 451.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.03
Quick Ratio 17.03
Altman-Z 8.9
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-93.55%
EPS Next Y-51.61%
EPS Next 2Y-31.31%
EPS Next 3Y-7.66%
EPS Next 5Y24.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-101.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-71.33%
EBIT Next 3Y-7.04%
EBIT Next 5YN/A
FCF growth 1Y-122.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.48%
OCF growth 3YN/A
OCF growth 5YN/A

VERA THERAPEUTICS INC / VERA FAQ

What is the ChartMill fundamental rating of VERA THERAPEUTICS INC (VERA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VERA.


What is the valuation status for VERA stock?

ChartMill assigns a valuation rating of 0 / 10 to VERA THERAPEUTICS INC (VERA). This can be considered as Overvalued.


How profitable is VERA THERAPEUTICS INC (VERA) stock?

VERA THERAPEUTICS INC (VERA) has a profitability rating of 1 / 10.